Venofer (iron Sucrose)

The dosage of Iron Sucrose is highly individualized and depends on the patient's body weight, hemoglobin levels, and the specific stage of chronic kidney disease (CKD). Healthcare providers typically aim to reach a cumulative dose of 1,000 mg of elemental iron to replenish stores.

• Hemodialysis-Dependent CKD (HDD-CKD): The standard dose is 100 mg of elemental iron (5 mL) administered during each dialysis session. This is usually repeated for 10 consecutive dialysis sessions to reach the 1,000 mg goal.
• Non-Dialysis Dependent CKD (NDD-CKD): The typical regimen is 200 mg of elemental iron (10 mL) administered on five different occasions within a 14-day period. Alternatively, some providers may administer 500 mg infusions on Day 1 and Day 14.
• Peritoneal Dialysis-Dependent CKD (PDD-CKD): The common dose is two infusions of 300 mg (15 mL) spaced 14 days apart, followed by one 400 mg (20 mL) infusion 14 days later.

Iron Sucrose is FDA-approved for the treatment of iron deficiency anemia in pediatric patients aged 2 years and older who have CKD.

• Children (2 years and older): The dosage is usually based on weight. For those on hemodialysis, the dose is typically 0.5 mg/kg (not to exceed 100 mg per dose) administered every two weeks for 12 weeks. For children with NDD-CKD or PDD-CKD, the dose is often 0.5 mg/kg (max 100 mg) administered at similar intervals.
• Children under 2 years: Safety and efficacy have not been established for infants and children under the age of 2.

Renal Impairment

Since Iron Sucrose is primarily indicated for patients with renal impairment, no specific dose adjustment is required for the degree of kidney failure itself. However, the timing of administration is often synchronized with dialysis schedules.

Hepatic Impairment

Caution is advised in patients with severe liver dysfunction. The liver is a primary storage site for iron (as ferritin). In patients with hepatitis or cirrhosis, the risk of iron overload or oxidative stress may be increased. Healthcare providers will monitor liver function tests and iron parameters closely.

Elderly Patients

In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Iron Sucrose must be administered by a healthcare professional in a clinical setting equipped to handle emergency allergic reactions. It is never self-administered.

• Slow IV Injection: The undiluted solution may be administered by slow intravenous injection at a rate of 1 mL (20 mg iron) per minute.
• IV Infusion: The dose may be diluted in a maximum of 100 mL of 0.9% NaCl and infused over at least 15 minutes.
• Storage: Vials should be stored at controlled room temperature (20°C to 25°C or 68°F to 77°F). Do not freeze. Once diluted, the solution should be used immediately.

Because Iron Sucrose is administered by healthcare professionals in a clinic or dialysis center, a missed dose usually involves a missed appointment. If you miss a scheduled session, contact your healthcare provider immediately to reschedule. Maintaining the schedule is vital for the effective replenishment of iron stores.

An overdose of Iron Sucrose can lead to acute iron toxicity. Symptoms may include:

• Severe hypotension (low blood pressure)
• Headache
• Dizziness
• Nausea and vomiting
• Abdominal pain
• Joint pain
• Hemosiderosis (excessive iron accumulation in tissues)

In the event of a suspected overdose, emergency measures include supportive care and, in severe cases, the use of iron-chelating agents (medications that bind to iron to help the body excrete it).

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance. Regular blood tests are necessary to ensure iron levels remain within a safe range.

Most patients tolerate Iron Sucrose well, but some may experience mild to moderate side effects. Common reactions include:

• Hypotension (Low Blood Pressure): This is the most frequently reported side effect, occurring in approximately 7-36% of dialysis patients. It may feel like lightheadedness, dizziness, or fainting, especially during or immediately after the infusion.
• Nausea and Vomiting: Some patients report an upset stomach or a feeling of queasiness shortly after administration.
• Headache: A dull or throbbing pain in the head that usually resolves within a few hours.
• Muscle Cramps: Specifically in the legs or back, often associated with the fluid shifts that occur during dialysis combined with the infusion.
• Dizziness: A sensation of spinning or instability.

• Diarrhea or Constipation: Changes in bowel habits, though less common than with oral iron.
• Taste Changes: A metallic taste in the mouth (dysgeusia) is frequently reported during the injection.
• Injection Site Reactions: Pain, swelling, or redness at the site where the IV was inserted.
• Fever and Chills: A mild 'flu-like' reaction that occurs a few hours after treatment.
• Arthralgia (Joint Pain): Aching in the joints that may last for 24-48 hours.

• Peripheral Edema: Swelling of the hands, ankles, or feet.
• Pruritus (Itching): Itchy skin without a visible rash.
• Tachycardia: An abnormally rapid heart rate.
• Chest Pain: Mild discomfort in the chest area (must be distinguished from cardiac events).

> Warning: Stop taking Iron Sucrose and call your doctor immediately if you experience any of these.

• Anaphylaxis: A life-threatening allergic reaction characterized by difficulty breathing, swelling of the face/throat, rapid pulse, and a severe drop in blood pressure. This typically occurs within minutes of starting the infusion.
• Severe Hypotension: A sudden, dramatic drop in blood pressure that can lead to loss of consciousness or organ damage.
• Hypersensitivity Reactions: Generalized rash, hives (urticaria), and wheezing.
• Iron Overload (Hemosiderosis): Long-term accumulation of iron in organs like the liver and heart, which can lead to organ failure. Symptoms include chronic fatigue and abdominal pain.
• Seizures: Though extremely rare, neurological disturbances have been reported in the context of iron toxicity or hypersensitivity.

The primary concern with long-term use of Iron Sucrose is the potential for iron overload. Excess iron is stored in the liver, heart, and endocrine glands. Over time, this can lead to:

• Cirrhosis: Scarring of the liver.
• Cardiomyopathy: Weakening of the heart muscle, leading to heart failure.
• Hyperpigmentation: A permanent darkening of the skin (bronzing).
• Increased Infection Risk: Some studies suggest that high levels of circulating iron can promote the growth of certain bacteria, potentially increasing the risk of infections in vulnerable patients.

As of 2024, Iron Sucrose (Venofer) does not carry an FDA Black Box Warning. However, it does carry significant 'Warnings and Precautions' regarding hypersensitivity reactions. Unlike older iron dextran products, a 'test dose' is not legally mandated by the FDA for Iron Sucrose, but many clinical protocols still recommend observing the patient closely for the first 30 minutes of the first infusion.

Report any unusual symptoms to your healthcare provider. Even mild symptoms should be documented to help your doctor adjust your treatment plan.

Iron Sucrose is a potent medication that must be administered with caution. The most critical safety concern is the risk of hypersensitivity reactions, including anaphylaxis. Patients should be monitored for at least 30 minutes following each injection to ensure no delayed reactions occur. Because it is administered intravenously, the onset of side effects can be rapid. Healthcare providers must have resuscitation equipment and emergency medications (like epinephrine and antihistamines) immediately available.

No FDA black box warnings for Iron Sucrose. While it is considered safer than iron dextran, the potential for serious allergic reactions remains a primary clinical focus.

• Allergic Reactions / Anaphylaxis Risk: Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported. Patients with a history of multiple drug allergies may be at higher risk.
• Hypotension: Iron Sucrose may cause low blood pressure. This is often related to the rate of administration. Slowing the infusion rate can frequently mitigate this risk. Patients should be seated or lying down during administration.
• Iron Overload: Excessive iron therapy can lead to the accumulation of iron in storage sites, leading to hemosiderosis. Periodic monitoring of hemoglobin, hematocrit, serum ferritin, and TSAT is essential to prevent this.
• Benzyl Alcohol Toxicity: Some formulations of parenteral drugs contain benzyl alcohol, which can be toxic to neonates. However, most Iron Sucrose formulations are preservative-free. Always check the specific product label.

To ensure safety and efficacy, your healthcare provider will order regular blood tests:

• Serum Ferritin: Measures the amount of stored iron in the body. Levels should typically be maintained between 100 ng/mL and 500 ng/mL in CKD patients.
• Transferrin Saturation (TSAT): Indicates how much iron is currently available for red blood cell production. The target is usually 20% to 50%.
• Hemoglobin/Hematocrit: Monitored every 2-4 weeks initially to assess the response to therapy.
• Liver Function Tests (LFTs): May be checked periodically in patients receiving long-term iron therapy to monitor for iron-induced liver stress.

Iron Sucrose can cause dizziness and hypotension. Patients are advised not to drive or operate heavy machinery for several hours after an infusion until they know how the medication affects them. If you feel lightheaded or faint after a treatment, do not attempt to drive.

There is no direct chemical interaction between Iron Sucrose and alcohol. However, alcohol can dehydrate the body and worsen the hypotensive effects (low blood pressure) of the medication. It is generally recommended to avoid alcohol on the day of your infusion.

Iron Sucrose does not cause a withdrawal syndrome. However, stopping the medication before the full course is completed will likely result in a failure to correct the anemia, leading to a return of fatigue and other symptoms. If treatment must be discontinued due to an allergic reaction, your doctor will switch you to a different class of iron or a different iron complex (like Ferric Carboxymaltose).

> Important: Discuss all your medical conditions, especially any history of liver disease, infections, or previous drug allergies, with your healthcare provider before starting Iron Sucrose.

• Oral Iron Supplements: Iron Sucrose should not be administered concomitantly with oral iron preparations (e.g., ferrous sulfate, ferrous gluconate). The clinical consequence is that IV iron can reduce the absorption of oral iron by saturating the transport mechanisms in the gut. Furthermore, combining both increases the risk of iron overload. Oral iron should be discontinued at least 24 hours before the first IV dose.

• Dimercaprol: This chelating agent, used to treat heavy metal poisoning, can form toxic complexes with iron. If a patient requires dimercaprol, Iron Sucrose must be withheld to avoid nephrotoxicity (kidney damage).
• Erythropoiesis-Stimulating Agents (ESAs): Drugs like Epoetin alfa or Darbepoetin alfa work in tandem with iron. While not a negative interaction, the dose of the ESA may need to be adjusted downward as iron stores are replenished, as the body will become more responsive to the ESA.

• ACE Inhibitors: Some studies suggest that patients taking ACE inhibitors (like lisinopril or enalapril) may have a slightly increased risk of hypersensitivity reactions when receiving IV iron. The mechanism is thought to involve the modulation of bradykinin levels. Healthcare providers should monitor these patients more closely for signs of flushing or itching.

Because Iron Sucrose is administered intravenously, traditional food interactions involving the stomach (like the 'grapefruit effect') do not occur. However, overall nutritional status is important. A diet high in Vitamin C can theoretically help the body utilize iron once it is released from the sucrose complex, though this is more relevant for oral iron.

• St. John's Wort: While no direct interaction exists, St. John's Wort can affect overall drug metabolism and should be disclosed to your doctor.
• Antioxidant Supplements: High doses of Vitamin E or other antioxidants might theoretically interfere with the oxidative processes involved in iron utilization, though clinical data is limited.
• Calcium Supplements: Unlike oral iron, IV Iron Sucrose does not interact with calcium in the gut. However, excessive calcium intake should be monitored in CKD patients for other reasons.

• Serum Iron and Ferritin: These levels will be artificially elevated for 1-2 weeks following an infusion. Blood tests to check iron status should ideally be performed at least 7 to 14 days after the last dose to get an accurate reading of the body's true iron stores.
• Magnetic Resonance Imaging (MRI): Iron is paramagnetic. High levels of circulating iron immediately after an infusion might theoretically interfere with the clarity of certain MRI scans, particularly those focusing on the liver or spleen. Inform your radiologist if you have received an iron infusion within the last 48 hours.

For each major interaction, the management strategy involves timing and monitoring. The primary strategy is the cessation of oral iron and the careful timing of blood draws to ensure that laboratory data reflects the patient's physiological state rather than the immediate presence of the drug.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter pain relievers and vitamins.

Iron Sucrose must NEVER be used in the following circumstances:

• Known Hypersensitivity: If a patient has had a documented severe allergic reaction (anaphylaxis) to Iron Sucrose or any of its components (including sucrose). The risk of a fatal re-exposure is too high.
• Evidence of Iron Overload: Patients with conditions like Hemochromatosis or Hemosiderosis already have excessive iron stores. Adding IV iron can cause rapid organ damage, particularly to the heart and liver.
• Anemia Not Caused by Iron Deficiency: If the anemia is due to other causes (such as Vitamin B12 deficiency, folate deficiency, or hemolytic anemia), Iron Sucrose will not be effective and will only risk iron toxicity.

Conditions requiring careful risk-benefit analysis include:

• Active Systemic Infection: Some clinicians believe that IV iron may 'feed' certain bacteria, potentially worsening an active infection. In cases of sepsis or severe localized infection, iron therapy is often delayed until the infection is resolved.
• Severe Liver Disease: Because the liver is the primary site for iron storage and processing, patients with decompensated cirrhosis or acute hepatitis may not be able to safely process the iron, increasing the risk of oxidative stress.
• History of Asthma or Eczema: Patients with a history of atopic diseases (allergic conditions) are statistically at a higher risk for developing hypersensitivity reactions to IV iron complexes.
• Low Blood Pressure (Hypotension): Since Iron Sucrose can lower blood pressure further, patients who are already hypotensive or 'dry' (dehydrated) after dialysis require very slow infusion rates and careful monitoring.

Patients who have had a mild reaction to other iron complexes (like Ferric Gluconate or Iron Dextran) may be able to tolerate Iron Sucrose, but only under extreme caution. There is a potential for cross-sensitivity among different parenteral iron products because they all share a similar iron-hydroxide core. However, the carbohydrate shell (sucrose vs. dextran vs. carboxymaltose) is often what triggers the specific allergic response.

> Important: Your healthcare provider will evaluate your complete medical history, including any previous reactions to IV medications, before prescribing Iron Sucrose.

Iron Sucrose is classified as Pregnancy Category B (under the old FDA system). This means that animal reproduction studies have failed to demonstrate a risk to the fetus, but there are no adequate and well-controlled studies in pregnant women.

• Trimester-Specific Risks: Iron deficiency anemia is common in the second and third trimesters. Iron Sucrose is generally reserved for pregnant women who cannot tolerate or do not respond to oral iron. Use in the first trimester is typically avoided unless the benefit clearly outweighs the risk, as organogenesis (organ formation) is occurring.
• Clinical Considerations: Untreated iron deficiency anemia in pregnancy is associated with adverse outcomes such as low birth weight and preterm delivery. Therefore, managing iron levels is critical.

Sucrose is a natural component of the body, and iron is naturally present in breast milk. Limited data suggest that the amount of iron that passes into breast milk following an IV Iron Sucrose infusion is minimal and unlikely to cause adverse effects in the nursing infant. However, mothers should monitor the infant for potential constipation or changes in stool color.

Iron Sucrose is approved for children aged 2 years and older with CKD.

• Growth Effects: There is no evidence that Iron Sucrose negatively impacts growth or development in children.
• Safety: The side effect profile in children is similar to that in adults, with hypotension and headache being the most common.
• Not Approved: It is not approved for children under 2 years of age or for children with anemia not related to CKD.

Clinical studies of Iron Sucrose did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.

• Fall Risk: Because elderly patients are more susceptible to orthostatic hypotension (dizziness upon standing), the blood pressure-lowering effect of Iron Sucrose poses a significant fall risk in this population.
• Renal Clearance: While the iron is processed by the liver/RES, the sucrose is cleared renally. Elderly patients with age-related declines in GFR may clear the sucrose component more slowly, though this is rarely clinically significant.

Iron Sucrose is specifically designed for this population. No dose adjustment is needed based on GFR. In patients on hemodialysis, the drug is typically administered into the venous line of the dialysis machine at the end of the session to ensure maximum delivery to the body.

In patients with hepatic impairment (Child-Pugh Class B or C), iron should be administered with extreme caution. The liver's ability to produce transferrin (the iron transport protein) may be reduced, leading to higher levels of non-transferrin-bound iron, which can be toxic. Regular monitoring of LFTs and ferritin is mandatory.

> Important: Special populations require individualized medical assessment and frequent monitoring of blood parameters.

Iron Sucrose is an iron replacement product that delivers iron in a form that mimics the body's natural iron-storage proteins. It is a complex of polynuclear iron(III)-hydroxide cores. These cores are non-covalently surrounded by sucrose molecules.

Upon intravenous administration, the complex remains stable in the plasma until it is engulfed by macrophages of the reticuloendothelial system (RES). Within the lysosomes of these macrophages, the acidic environment and enzymes break the complex apart. The iron is then released into the intracellular pool. From here, it can be stored as ferritin or transported out of the cell via ferroportin. Once in the blood, it binds to transferrin, which delivers it to the bone marrow for incorporation into hemoglobin during the maturation of red blood cells.

The pharmacodynamic response to Iron Sucrose is measurable by an increase in reticulocyte count (new red blood cells) within 7-10 days of starting therapy, followed by a rise in hemoglobin and hematocrit levels. The duration of effect depends on the patient's rate of iron loss (e.g., through ongoing dialysis or bleeding) and the rate of erythropoiesis. There is no evidence of tolerance development; the body continues to utilize the iron as long as a deficiency exists.

| Parameter | Value |

|---|---|

| Bioavailability | 100% (Intravenous) |

| Protein Binding | >90% (as Transferrin) |

| Half-life | ~6 hours (terminal) |

| Tmax | Immediate (end of infusion) |

| Metabolism | Dissociation in the RES |

| Excretion | Renal (Sucrose component ~75%) |

• Molecular Formula: [Na2Fe5O8(OH)·3(H2O)]n·m(C12H22O11)
• Molecular Weight: Approximately 34,000 to 60,000 Daltons (as a complex).
• Solubility: Highly soluble in water; the solution has a pH of 10.5 to 11.0.
• Structure: A brown, amorphous powder in its solid form, it consists of a central iron-hydroxide core with a sucrose shell that prevents rapid iron release and toxicity.

Iron Sucrose is categorized as a Parenteral Iron Replacement agent. It is part of a therapeutic class that includes other IV iron complexes such as:

• Ferric Gluconate (Ferrlecit)
• Iron Dextran (INFeD)
• Ferric Carboxymaltose (Injectafer)
• Ferumoxytol (Feraheme)

Compared to iron dextran, Iron Sucrose has a lower molecular weight and a lower risk of anaphylaxis, making it a preferred choice in many clinical settings.